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Introduction:
Effective tight glycemic control (TGC) can improve outcomes, but is difficult to achieve. In silico virtual patients 
and trials offer significant advantages in cost, time and safety for designing effective TGC protocols. However, 
no such method has been fully validated. This study tests 2 matched cohorts from the Glucontrol trial treated 
with different protocols. The goal is to validate the ability of in-silico virtual patient models and methods to 
accurately predict patient-specific and clinical trial glycemic outcomes. 
Methods:
The analysis uses records for a 211 patient subset of the Glucontrol trial (Liege, Belgium). Glucontrol-A (N=142) 
targeted 4.4-6.1mmol/L and Glucontrol-B (N=69) targeted 7.8-10.0mmol/L. Cohorts were matched by APACHE II 
score, age and sex (p>0.3). The Glucontrol A cohort was slightly older (p=0.04). Virtual patients are created by 
fitting a clinically validated model to the data, yielding time varying insulin sensitivity profiles (SI(t)) that create 
in-silico virtual patients.  
Model fit and intra-patient (forward) prediction are used to validate individual in-silico virtual patients. Self-
validation (tests A protocol on Group A virtual patients; and B protocol on B virtual patients) and cross-
validation (tests A protocol on Group B virtual patients; and B protocol on A virtual patients) assess ability to 
predict a clinical trial result. 
Results:
Model fit errors were small (<0.25%) for Group A, Group B and the entire cohort (A+B), indicating model fitness. 
Median prediction errors were: 4.3, 2.8 and 3.5% for Group A, Group B and (A+B), indicating individual virtual 
patients were accurate representations of real patients. Self and cross validation results were within 1-10% of the 
clinical data for both Group A and Group B. Self validation indicated clinically insignificant model and 
compliance errors. Cross validation clearly showed that the virtual patients enabled by identified patient-specific 
SI(t) profiles can accurately predict the performance of TGC protocols different from those used to create the 
virtual patients. 
Conclusions:
This study validates these virtual patients and in silico virtual trial methods, and clearly shows they can 
accurately simulate, in advance, the clinical results of a TGC protocol, enabling rapid in silico protocol design 
and optimization. It is the first rigorous validation of a virtual in-silico patient and virtual trials methodology. 
